Figure 3From: A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus Mean course of the primary efficacy variable (THI-12 score) 1. Intention-to-treat, last observation carried forward. 2. Difference of least square means 50 mg vs. placebo and p-values from ANCOVA with treatment and center as factor, baseline as covariate 3. Difference from baseline, * p < 0.05Back to article page